secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046163
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon reports Q4/FY24 net loss $22.8M/$80.6M; ACR-368 endometrial cancer cORR 35% in BM+ patients
--------------------------------------------------------------------------------

- Cash $184.6M as of Dec 31, 2024; runway extended into 2027.
- ACR-368 in BM+ endometrial cancer: 35% cORR, 80% DCR; in relapsed patients cORR 50% with mDOR >10 months.
- Phase 1 ACR-2316 cleared doses 1-2; dose 3 shows tumor shrinkage; target engagement confirmed.
- Endometrial cancer prioritized; ovarian and bladder deprioritized due to competition/low BM+ rate.
- R&D expenses $64.0M for FY24 vs $46.0M in FY23, driven by ACR-368 and ACR-2316 clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017025046163/0000950170-25-046163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017025046163/acrv-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer